Tech Company Financing Transactions
Tilt Biotherapeutics Funding Round
Tilt Biotherapeutics, operating out of Helsinki, secured $10.7 million from Lifeline Ventures and Tesi.
Transaction Overview
Company Name
Announced On
6/14/2022
Transaction Type
Venture Equity
Amount
$10,700,000
Round
Undisclosed
Investors
Lifeline Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance Phase I/II programs in Europe and the US, using TILT-123 plus immune checkpoint inhibitors against a range of cancers including ovarian, head & neck, and lung.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Haartmaninkatu 3, Tukholmankatu 8 B, Biomedicum 2B, (2nd flo
Helsinki, 00290
FI
Helsinki, 00290
FI
Phone
Undisclosed
Website
Email Address
Overview
TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Akseli Hemminki
VP - Bus. Development
Víctor Carrascón
VP - R & D
Riikka Havunen
Browse more venture capital transactions:
Prev: 6/14/2022: Collaborative Robotics venture capital transaction
Next: 6/14/2022: LiveView Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs